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Abstract 
The present study has been undertaken to apply the concept of nanoparticulate 
mucopenetrating drug delivery system for complete eradication of Helicobacter 
pylori (H. pylori), colonised deep into the gastric mucosal lining. Most of the 
existing drug delivery systems have failed on account of either improper 
mucoadhesion or mucopenetration and no dosage form with dual activity of 
adhesion and penetration has been designed till date for treating H. pylori 
induced disorders. In the present study, novel chitosan-alginate polyelectrolyte 
complex (CS-ALG PEC) nanoparticles of amoxicillin have been designed and 
optimized for various variables such as pH and mixing ratio of polymers, 
concentrations of polymers, drug and surfactant, using 3
3 Box-Behnken design. 
Various studies like particle size, surface charge, percent drug entrapment, in-
vitro mucoadhesion and in-vivo mucopenetration of nanoparticles on rat models 
were conducted. The optimised FITC labelled CS-ALG PEC nanoparticles have 
shown comparative low in-vitro  mucoadhesion with respect to plain chitosan 
nanoparticles, but excellent mucopenetration and localization as observed with 
increased fluorescence in gastric mucosa continuously over 6 hours, which 
clinically can help in eradication of H. pylori. 
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Introduction 
Amoxicillin is a well tolerated, broad-spectrum, beta-lactam antibiotic for the treatment of a 
wide range of bacterial infections, including Helicobacter pylori (H. pylori). It inhibits the cell 
wall biosynthesis during the proliferation phase of H. pylori at pH 5 and above, and is first 
line drug along with Clarithromycin or Metronidazole and omeprazole for the treatment of 
H. pylori induced peptic and duodenal ulcers. Clinical studies using amoxicillin showed 
least resistance compare to Clarithromycin or Metronidazole against H. pylori [1]. Inspite of 
various antibiotic combinations studied against H. pylori,  none have shown complete 
eradication of bacterium. The incomplete eradication of H. pylori  may be due to sub-
bactericidal concentration of antibiotics in the gastric mucosal region, both from the lumen 
of the stomach and from the gastric supply. Hence local diffusion of drug into gastric 
mucosa is essential for therapeutic efficacy [2, 3]. The stability of commonly used 
antibiotics in the triple therapy such as amoxicillin, clarithromycin, or metronidazole is not 
more than 3–4 hours in gastric environment [4].  
Various delivery systems of Amoxicillin have been prepared in recent time for increasing 
its local availability and efficacy such as polymer matrix tablets [5], gastroretentive floating 
systems [6–9], bioadhesive systems [10]. Most of these studies emphasised on increasing 
the retention time of drug in the stomach and increasing the stability of antibiotics in acidic 
environment of stomach. But these systems could not assist in the complete eradication of 
bacterium.  
Since last decade, the strategy for effective delivery of antibiotics to H. pylori has shifted to 
the use of mucoadhesive micro or nano particulate based delivery systems based on the 
fact that mucoadhesive particulate show longer retention in stomach and thus deliver the 
antibiotic locally in the stomach mucosa for longer duration [11]. Most of mucoadhesive 
systems are prepared out of positively charged polymers such as Chitosan [12, 13], 
chitosan coated sodium alginate [14], chitosan coated gellan gum [15], Gelatin [16], 
Carbomer 934P [17], cellulose acetate butyrate (CAB) coated cholestyamine [18], Glidian 
polymeric protein obtained from gluten [19] etc. These systems provide an intimate contact 
with the negatively charged (due to sialic acid or carboxyl or sulphate groups in the mucus 
glycoprotein) mucus membrane due to polyvalent adhesive interaction or electrostatic 
attraction, H-bond formation, van-der-Waal forces and other [20]. The system has an 
additional advantage of protecting acid sensitive drugs against acid degradation and offers 
effective drug diffusion across the mucus layer.  
However H. pylori has a unique way of survival in harsh acidic environment of the stomach 
by colonizing deep in the gastric mucosal layer and get adhered to the surface of mucus 
epithelial cells by adhesion and penetration using flagella [21]. Mucoadhesion though aid 
in increasing the gastric residence time of particles, the thick viscoelastic mucosal gel does 
not allow antimicrobial drugs to penetrate through it uniformly [22]. Swelling of the polymer 
may hinder docking it in gastric mucus and strong mucoadhesion decrease the mobility 
and thus interpenetrate penetrability in to mucus. In addition, gastric motility and 
proteolytic activity make mucus turnover intense there by make gastric residence of 
formulation shorter [23]. Hence  efficient adherence to mucus could make the system 
incapable of penetrating across the mucus layer and entering the underlying epithelia [24].   Amoxicillin Loaded Chitosan–Alginate Polyelectrolyte Complex Nanoparticles as Mucopenetrating … 675 
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To overcome these limitations, the particulate system, are required to penetrate the mucus 
membrane and deliver the drug close proximity to the site of H. pylori infection. Many 
researchers reported the preparation of particulate systems capable of penetrating mucus 
membrane. Some of these reports include polyethylene glycol (PEG) coated polystyrene 
based non-adhesive nanoparticle were reported to effectively penetrating sputum of cystic 
fibrosis patients [25], PEG-PSA(poly sebasic acid)  based biodegradable nanoparticles 
rapidly penetrating human mucus barrier [26], insulin loaded polyethylene glycol-grafted 
chitosan  (PEG-g-chitosan)  nanoparticle for the nasal absorption [27], DNA coated 
biodegradable (poly lactide co-glycolic acid) PLGA nanoparticle for the gene delivery in 
gastric mucus [28]. These studies emphasized on modifying the surface chemistry of the 
particulate system such as Chitosan, to minimise the mucoadhesion property by shielding 
the cationic charge. Along with shielding charge, particle size may also play a very crucial 
role in the penetration of particle. Particle size less than the mesh size of the mucin fiber 
are reported to exhibit the good mucin penetration property [25, 27].  
The present  work is an attempt to develop a novel bi-specific, biodegradable, 
mucopenetrating  chitosan-alginate polyelectrolyte complex (CS-ALG-PEC) nanoparticle 
system for delivery of Amoxicillin to deep mucus layers near the sanctuary of the H. pylori. 
Cationic polymer, Chitosan was derivatized by the interaction of its surface amino groups 
with carboxylic acid groups of sodium alginate in absence of Calcium/ magnesium ions 
which is an unique approach to eradicate H. pylori [29]. 
Various formulation and process variables viz. concentrations and ratio of polymer / drug / 
surfactant, mixing time and speed, pH, homogenization speed and time etc. influence the 
characteristics of nanoparticulate delivery systems needing optimization. The concept of 
mathematical modelling and statistical approach of optimisation, has been considered 
more powerful than traditional methods of changing one factor at a time for multi factor 
optimization [30]. The Box-Behnken design (BBD), an independent quadratic design which 
does not contain any embedded factorial or fractional factorial design is applied here to 
optimize the process [31–34]. The finally optimized nanoparticles were studied for in vitro 
mucoadhesion and in vivo mucopenetration studies on rat model. 
Results and Discussion 
Preparation & optimisation of CS-ALG PEC nanoparticles 
The preparation of CS–ALG PEC nanoparticles was based on ionotropic gelation process 
by mixing aqueous phases of the polycationic CS and polyanionic ALG at room 
temperature. Due to the higher viscosity of CS solution, a number of experiments were 
performed by varying the concentration of CS and ALG to screen the appropriate 
concentration range, pH and mixing ratio of polymeric solutions yielding turbid solution 
without aggregation.  
pH plays an important role in the formation of nanoparticles which affect the size [35]. 
Preliminary studies were performed by interacting CS and ALG at various pH range (pH  
3–6 for CS and pH 3–7 for ALG). The final pH selected for CS and ALG solutions was pH 
5.0 and pH 5.5 respectively based on the size of the nanoparticles obtained without 
aggregation. Increase in pH of CS solution beyond 5.0 showed precipitation particularly 
when pH is approaching the pKa value of CS (6.5). In addition, pH of CS solution when 676  S. Arora et al.:   
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reduced below 5.0 yielded desecrate particles which were difficult to recover. This is 
probably due to high degree of protonation of amino group of CS leading to high reaction 
rate with ALG. [36]. Similar is the case with ALG where the COO
−  groups affect the 
formation of nanoparticles, variation in pH from the optimized value (5.5) showed 
undesirable particle size of the nanoparticles. Rate of addition of ALG into CS solution was 
also found to a critical parameter in nanoparticle formation [37]. Studies with different 
mixing ratios of CS: ALG ranging from 1:1 to 10:1 revealed the need for large volume of 
CS in comparison to ALG. The optimum ratio was found to be 9:1. Larger the volume of 
CS, more is the spatial interaction between CS and ALG under stirring condition, hence 
better nucleation. Fluorescent nanoparticles were also prepared in the same way using 
FITC for visualization. 
A direct relationship between the particle size and the CS concentration was observed in 
pre-optimization studies. Also, the concentration of surfactant (Pluronic F 127) influenced 
the entrapment efficiency and dissolution of drug. The final concentration range selected 
for optimization study using Box Behnken design was 0.02–0.06 % w/v of CS, 0.1 % w/v of 
ALG, 0.01–0.04 % w/v of Amoxicillin and 0.0–0.025 % w/v solution of Pluronic F-127 
(surfactant) as tabulated below:  
Tab. 1.  Variables in Box–Behnken Design 
Factors  Units  Levels used actually (coded) 
Low (−1)  Medium (0)  High (1) 
Chitosan Concentration  %w/v  0.02  0.040  0.060 
Drug Concentration  %w/v  0.01  0.025  0.040 
Surfactant Concentration  %w/v  0.00  0.012  0.025 
Dependent Variables  Units  Constraints 
Y1 = Particle Size  nm  Y1 ≥ 600 
Y2 = Zeta Potential  mV  Y2 ≥ 35.04 
Y3 = PDE  %  Maximize 
 
At a concentration of 0.02 % w/v of CS, the particle size of the nanoparticles was found to 
vary between 264 nm and 321 nm. At 0.04% and 0.06% w/v concentration of CS the size 
of nanoparticles varied between 382 nm and 600 nm and > 601 nm, respectively and the 
results are tabulated in Table 2. 
Zeta potential less than -30 mV or higher than +30 mV can be an indicator to assure the 
stability of nanoparticulate systems [38]. Zeta potential of CS ALG PEC nanoparticles 
depends on the total protonated amino groups on CS. Amino groups interact with acidic 
groups of ALG for neutralization as described earlier. The zeta potential remained above > 
+ 35 mV at our selected pH range for CS and ALG solutions. This confirms that the system 
remained stable without aggregation. Also the net positive zeta potential indicates the 
presence of free surface amino groups on the nanoparticulate delivery system which will 
help in initial adhesion to gastric mucosa. The observed zeta potential for our prepared 
nanoparticles was between 35.04 mV and 61.9 mV (Table 2). 
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Tab. 2.  Observed responses for Box-Behnken design for CS-ALG PEC nanoparticles 
 
The best fit model generated from the software (Design Expert 4.0 trial version) for the 
observed responses from 15 formulations as per Table 1 (particle size (Y1), zeta potential 
(Y2) and PDE (Y3)) showed the linear model for particle size and PDE, and quadratic 
model for zeta potential on the basis of p values (Table 3).  
Eq. 1.  Particle Size (Y1) = 482.64 + 166.87 * A + 42.17 * B +1.87 * C (Linear Model) 
 
Eq. 2.  Zeta Potencial (Y2) = 59.68 + 3.89 A − 2.34 B − 1.15 C − 2.32 A B − 0.57 A C + 
2.73 * B * C − 4.49 * A
2 − 11.08 * B
2 + 4.26 * C
2 (Quadratic) 
 
Eq. 3.  PDE (Y3) = 55.01 * 18.91 * A − 22.35 * B 5.04 * C (Linear Model) 
The values of the coefficients for CS, drug and surfactant relates to the effects of the 
factors  -  particle size, zeta potential and PDE and their comparative significance of 
nanoparticulate systems are shown in Table 4.  
 
 
Formulation 
Code 
Chitosan 
(% w/v) 
Drug 
(%w/v) 
Surfactant 
(%) 
Particle Size 
(Y1) (nm) 
Zeta 
Potential 
(Y2) (mV) 
PDE (%) 
(Y3) 
F1  0.02  0.01  0.012  265±16  41.59±3.9  61.5±4.6 
F2  0.06  0.01  0.012  633±23  57.81±3.1  91.6±4.0 
F3  0.02  0.04  0.012  300±19  35.04±2.4  23.5±3.1 
F4  0.06  0.04  0.012  638±27  41.97±2.8  47.5±4.3 
F5  0.02  0.025  0.000  268±18  56.75±3.7  24.0±2.9 
F6  0.06  0.025  0.000  616±24  61.90±4.1  66.4±2.4 
F7  0.02  0.025  0.025  321±21  58.15±3.9  33.2±3.6 
F8  0.06  0.025  0.025  601±23  60.99±2.6  88.0±3.5 
F9  0.04  0.01  0.000  382±17  57.12±3.5  79.6±2.8 
F10  0.04  0.04  0.000  574±25  53.46±3.2  31.8±4.1 
F11  0.04  0.01  0.025  414±22  46.79±3.3  84.9±4.3 
F12  0.04  0.04  0.025  519±29  54.08±4.6  36.0±4.5 
F13  0.04  0.025  0.012  600±18  59.22±4.2  52.4±2.9 
F14  0.04  0.025  0.012  508±18  59.76±2.9  52.0±3.8 
F15  0.04  0.025  0.012  594±21  60.06±3.6  52.8±4.7 678  S. Arora et al.:   
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Tab. 3.  Summary of Results describing Regression Analysis for responses  
Y1, Y2 and Y3 
Models  Sequential 
p-Value  R² Value  Adjusted  
R² 
Predicted 
R²  % C.V.  Remarks 
Response 
(Y1)             
Linear model  0.0001  0.8362  0.7915  0.7447  13.46  Suggested 
Second 
order  0.8927  0.8477  0.7334  0.5905  15.22   
Quadratic 
model  0.1224  0.9477  0.8534  0.4199  11.29   
Response 
(Y2)             
Linear model  0.5116  0.1820  −0.0411  −0.6391  15.8   
Second 
order  0.8994  0.2367  −0.3357  −2.5908  17.9   
Quadratic 
model  0.0234  0.8688  0.6327  −1.0937  9.38  Suggested 
Response 
(Y3)             
Linear model  < 0.0001  0.9409  0.9248  0.8762  11.54  Suggested 
Second 
order  0.8083  0.9473  0.907817  0.731027  12.78   
Quadratic 
model  0.7467  0.9579  0.882211  0.327505  14.45   
Regression equations of the fitted models  
Y = b0 + b1A + b2B + b3C + b12AB + b13AC + b23BC + b11A
2 + b22B
2 + b33C
2 
 
 
A direct relationship was observed between the concentration of CS and particle size, zeta 
potential and PDE. There was a marked increase of all these three parameters when the 
concentration increased from 0.02–0.06 % (Table 3). It is reported that a synergistic effect 
exists if the regression equation for a response parameter shows positive value while 
antagonistic effect in case it is negative [39].  Similarly, the results in Table 3 indicate 
synergistic interaction between the concentration of CS and surfactant on the responses 
Y1, Y2 and Y3, whereas concentration of drug showed antagonistic effect on Y3.  
Three-dimensional response surface plots drawn for the graphical optimization of 
Amoxicillin-loaded CS-ALG PEC mucoadhesive systems are presented in Figure 1.  
It was observed that at a constant concentration of surfactant i.e. 0.025% w/v, the PDE of 
nanoparticles increased with increasing concentrations of CS and decreased with 
increasing concentration of drug. Higher concentrations of drug resulted in lower PDE and 
major proportion was washed away in supernatant during separation of nanoparticles.  
   Amoxicillin Loaded Chitosan–Alginate Polyelectrolyte Complex Nanoparticles as Mucopenetrating … 679 
Sci Pharm. 2011; 79: 673–694 
Tab. 4.  Coefficients for the particle size, zeta potential and % Entrapment efficiency 
Term  Particle size (nm)  Zeta potencial (mV)  PDE 
Coeff.  SE  Range*  Coeff.  SE  Range*  Coeff.  SE  Range* 
Intercept  482.64  16.78  445.72 to 
519.57  59.68  2.91  52.21 to 
67.15  55.01  1.64  51.40 to 
58.62 
A-Chitosan 
Conc.  166.88  22.97  116.32 to 
217.43  3.89  1.78  −0.68 to 
8.47  18.91  2.24  13.97 to 
23.85 
B-Drug 
Conc.  42.18  22.97  −8.30 to 
92.73  −2.35  1.78  −6.92 to 
2.23  −22.36  2.24  −27.30 
to 17.42 
C-
Surfactant  
Conc. 
1.88  22.97  −48.68 to 
52.43  −1.15  1.78  −5.73 to 
3.42  5.04  2.24  0.10 to 
9.98 
AB  –  –  –  −2.32  2.52  −8.79 to 
4.15  –  –  – 
AC  –  –  –  -0.58  2.52  −7.05 to 
5.89  –  –  – 
BC  –  –  –  2.74  2.52  −3.73 to 
9.21  –  –  – 
A²  –  –  –  −4.50  2.62  −11.23 to 
2.24  –  –  – 
B²  –  –  –  −11.08  2.62  −17.82 to 
−4.35  –  –  – 
C²  –  –  –  4.26  2.62  −2.47 to 
11.00  –  –  – 
* The range indicates the lower and upper value of coefficients at 95% confidence interval. 
 
 
Tab. 5.  Composition of Checkpoint formulations, predicted and experimental values of 
response variables and percentage prediction error with 95% Confidence 
Interval. 
 
Optimized 
formulation 
Response 
Variable 
Predicted 
value 
Experimental 
value 
Percentage 
prediction 
error 
95% Confidence 
Interval 
0.06:0.01:0.019  Y1  600  638.1  6.35  516.80 to 683.10 
  Y2  51.65  60.06  16.28  40.02 to 63.23 
  Y3  98.28  91.23  −7.17  89.82 to 106.00 
0.06:0.01:0.020  Y1  600  601.7  0.28  516.80 to 683.10 
  Y2  51.63  59.76  15.75  40.01 to 63.21 
  Y3  97.94  89.95  −8.16  89.59 to 105.70 
0.06:0.01:0.018  Y1  599.61  616.4  2.80  516.10 to 682.80 
  Y2  51.66  59.22  14.63  40.05 to 63.26 
  Y3  97.51  91.84  −5.81  89.22 to105.54 680  S. Arora et al.:   
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The optimum formulation of drug-loaded CS-ALG PEC nanoparticles was selected based 
on the criteria of attaining the maximum value of entrapment efficiency and by applying 
constraints on Y1 ≥ 600 and Y2 ≥ +35 mV (Table 1). The formulation composition with CS 
0.06%, drug 0.01% and Pluronic F-127 (surfactant) 0.019% w/v was found to fulfil 
requisites of an optimum formulation. The optimized formulation with the particle size, zeta 
potential and the PDE as 651 nm, +59.76 mV and 91.23% respectively has been used for 
the rest of the study. 
For all of the three checkpoint formulations, the results of the evaluation for particle size, 
zeta potential and entrapment efficiency were found to be within the 95% confidence 
interval limits (Table 5).  
   
(a)  (b) 
 
(c) 
Fig. 1.  Response surface plot showing effect of Drug and Chitosan concentration on  
a) Particle size (Y1), b) Zeta potential (Y2) and c) % Drug Entrapment (Y3). 
Percentage prediction error helped in the validation of generated regression equations. 
Linear correlation plots between the actual and the predicted response variables (Figure 2) 
showed the scatter of the residuals versus actual values for better representing the spread 
of the dependent variables under present experimental settings. For validation of RSM 
results, the experimental values of the responses were compared with that of the 
anticipated values and the prediction error for the three response variables were found to 
vary  between  −8.16% and +16.28%. The low magnitudes of errors as well as the 
significant values of correlation validated the proposed RSM and proved the high 
prognostic ability of the Box-Behnken designs in formulation of nanoparticles.   Amoxicillin Loaded Chitosan–Alginate Polyelectrolyte Complex Nanoparticles as Mucopenetrating … 681 
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(a) Particle size 
 
(b) Zeta potential 
 
(c) Percent Drug  
Entrapment 
 
Fig. 2.  Linear correlation plots between actual and predicted values of (a) Particle size; 
(b) Zeta potential; (c) Percent Drug Entrapment. 
Stability of Amoxicillin in simulated gastric fluid (pH 1.2) 
The drug stability studies in SGF (pH1.2) showed that the drug degraded up to 85% (n=3) 
in acidic environment of the stomach in 4 hrs as depicted (Figure 3). Similar studies 
performed on CS-ALG PEC nanoparticles showed the decreased degradation of drug. The 
amoxicillin-loaded CS–ALG PEC nanoparticles showed 50%, 67% and 76 % release of 
amoxicillin at 2, 4 and 6 hours, respectively, which indicated the protective efficiency of 
nanoparticulate delivery system in gastric environment even after 6hrs.  This protective 682  S. Arora et al.:   
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behaviour can be attributed to the existence of amoxicillin in inner non-hydrated part of 
nanoparticles as in other matrix systems. Thus CS-ALG PEC nanoparticles can be utilised 
as sustained release gastroretentive delivery system for antibiotics like Amoxicillin, 
Clarithromycin or Metronidazole in eradication of H. pylori where antibiotic formulations fail 
to deliver the minimum inhibitory concentration in gastric mucosa due to instability at low 
pH & short residence time in the stomach [12]. 
in vitro stability studies of Amoxicillin
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Fig. 3.  In vitro stability of amoxicillin in simulated gastric fluid (pH 1.2) (n = 3). 
Characterization of Nanoparticles: 
The Scanning electron micrographs of freeze dried optimised amoxicillin loaded CS-ALG 
PEC nanoparticles at 200X magnification are showed in figure 4. The nanoparticles were 
seen as distinct spherical, consistent solid surface with porous structure. The observed 
microporous matrix structures of polyelectrolyte complex can be formed due to 
electrostatic interactions between anionic groups from sodium alginate and cationic groups 
from CS. [40]  
 
Fig. 4.   SEM micrograph of amoxicillin loaded CS-ALG polyanionic nanoparticles   Amoxicillin Loaded Chitosan–Alginate Polyelectrolyte Complex Nanoparticles as Mucopenetrating … 683 
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CS, ALG and CS–ALG PEC nanoparticles were analysed using FT-IR spectrophotometer 
for characteristic absorption bands, indicative of their interaction as shown in Figure 5. The 
peak at ~1640 cm
−1 in both the CS and CS–ALG PEC nanoparticles spectra was due to 
the unreacted NH2-groups of CS. Similarly, peaks observed at ~820 cm
−1 and ~1320 cm
−1 
in FT-IR spectra of ALG and CS–ALG PEC nanoparticles represent unreacted -COOH 
groups of ALG. The characteristic peak observed at 1447 cm
−1 (salt of carboxyl group) in 
the FT-IR spectrum of nanoparticles was attributed to the ionic interaction between these 
two reactive groups [41]. 
 
Fig. 5.   FTIR spectra of CS-ALG PEC nanoparticles with Amoxicillin  
Drug release profile 
The in vitro drug release study of the optimized formulation in SGF (pH 1.2) showed about 
76% of release of Amoxicillin over a period of 6 h. (Figure 6) As shown, a fast release of 
drug (~49%) is observed in first two hours which is further sustained 57.5%, 65.7% & 
76.5% in 3
rd, 4
th & 6
th hour respectively. The % drug release data from the mucoadhesive 
CS–ALG PEC nanoparticles followed the Higuchi  model (k=32.42h
−1  r
2  = 0.9905).  By 
applying the % drug release data in Korsmayer or power model to understand the release 
mechanism, the release exponent ‘n’ value was found out as 0.618, which indicates non-
Fickian (anomalous) release. This can be attributed to presence of unbound drug on the 
surface of nanoparticles or high swelling degree of these poly electrolyte complexes.[19] 
The release mechanism of Amoxicillin from the CS-ALG PEC nanoparticles refers to a 
combination of both diffusion and erosion controlled drug release, which is attributed to the 
rapid hydration of CS and ALG resulting in swelling & erosion of poly-ionic complexes. The 
observed release mechanism by diffusion would be useful in stomach specific delivery 
systems. [40]. 
In-vitro mucoadhesion studies  
The Bioadhesive force studies on optimised CS-ALG PEC nanoparticles revealed the 
detachment stress up to 14.98 x 10
3 dyne/cm
2 (n=3). The in vitro mucoadhesion studies 
using  the  FITC-labelled CS-ALG PEC nanoparticles  and FITC-labelled Chitosan-
Tripolyphosphate (TPP) nanoparticles showed mucoadhesive  capacity  with a percent 
mucoadhesion of 75.94 ± 3.2% and 88.5 ± 6.2% (n=3), respectively. The cationic amino 684  S. Arora et al.:   
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groups present on the chitosan interact electrostatically with mucin glycoproteins, sialic 
acid and other anionic moieties present on gastric mucosa [42]. The decrease in muco-
adhesive capacity of prepared CS-ALG PEC nanoparticles can be attributed to decrease 
in surface amino groups by ionic interaction with carboxylic ions of sodium alginate [24]. 
This decline in mucoadhesion can help the nanoparticles to infiltrate at faster rate in 
gastric mucosa thus proving the utility of prepared CS-ALG PEC nanoparticles better for 
better penetration and accumulation at the site of H. pylori infection beneath mucosa. 
  
Fig. 6.  In vitro release profiles of the optimised formulation of CS–ALG PEC 
nanoparticles in SGF, pH 1.2 
In-vivo mucopenetration studies 
The microscopic studies revealed the mucopenetration  as well as  localisation of quite 
good number of FITC labelled CS-ALG PEC nanoparticles into the gastric mucosa during 
6 hours study. (Figure 7, 8).  
 
Fig. 7.  In-vivo mucopenetration studies of CS-ALG PEC on Gastric mucosa (Digital 
microscope magnification-100X)    Amoxicillin Loaded Chitosan–Alginate Polyelectrolyte Complex Nanoparticles as Mucopenetrating … 685 
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Fig. 8.  In-vivo mucopenetration studies of CS-ALG PEC on Gastric mucosa 
(Fluorescent microscope magnification-40X)  
The amoxicillin loaded FITC labelled CS-ALG PEC nanoparticles have shown good initial 
gastric mucoadhesion and finally penetrated deep in to the mucosal layers near the gastric 
epithelial cells of antrum region with time, as observed with increased fluorescence in this 
site of mucosa continuously over 6  hours. (Fig. 8) The observed  mucopenetration is 
attributed to decrease in surface positivity & hence mucoadhesion of CS-ALG PEC 
nanoparticles in comparison to plain chitosan nanoparticles. Thus the results confirm the 
earlier studies on modifying the surface chemistry &/or shielding or decreasing the cationic 
charge on polymers like chitosan in order to increase the motility in mucosa [25–27]. 
These studies indicate the possible improvement in the efficacy of CS-ALG PEC 
nanoparticles and may significantly reduce the chances of incomplete eradication and 
systemic side effects.  
Conclusion 
A novel mucopenetrating CS-ALG PEC nanoparticulate system composed of chitosan and 
sodium alginate was successfully optimized using 3
3  Box-Behnken design of experi-
mentation. The optimum complexation was found using chitosan at pH 5 and sodium 
alginate at pH 5.5 and the most effective composition of CS-ALG PEC nanoparticles was 
chitosan 0.06 % w/v, Amoxicillin (drug) 0.01 % w/v and Pluronic F-127 (surfactant) 0.019 
% w/v. The in vitro drug release studies for 6 hrs revealed the gastro protective nature of 
PEC system and diffusion through swollen polymeric complex as main drug release 
mechanism.(Higuchi model)  The  in vitro mucoadhesion  studies (76 % mucoadhesion) 
confirmed the decrease in mucoadhesion of chitosan by ionic interaction with anionic 
sodium alginate. The in vivo mucopenetration studies using Fluorescent FITC labelled CS-
ALG PEC nanoparticles  showed increased intensity of fluorescence near the gastric 
epithelial layers confirming mucopenetration  as well as localization of nanoparticles in 
deep  mucosal region. The results proved the concept of increased mobility of 
nanoparticles in the gastric mucus by decreasing the surface amino groups of CS on ionic 
interaction with carboxylic groups of ALG. Hence the current novel CS-ALG PEC 
nanoparticles can be utilised for suggested transmucosal delivery of antibacterial drugs in 
eradication of H. pylori. 686  S. Arora et al.:   
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Experimental 
Materials 
Chitosan (CS) (viscosity 200–400 mPas), Pluronic F-127 (cell culture tested) and 
Fluorescein isothiocynate isomer l-Celite (FITC) were purchased from Sigma Aldrich 
(USA). Sodium Alginate (ALG) and D-(+)-Trehalose dihydrate were purchased from 
HiMedia Laboratories Pvt. Ltd (Mumbai). Amoxicillin trihydrate was provided as a  gift 
sample from Siemens Laboratories (India) Gurgaon. Simulated gastric fluid (SGF) was 
prepared as per USP XXIX. Double distilled water was used in all the preparations. All 
other solvents and chemicals used were of analytical grade. 
Preparation of CS-ALG PEC nanoparticles 
The nanoparticles were prepared by modified ionic gelation method [35].  A mixture of 
chitosan, pluronic and amoxicillin was prepared in varying concentrations of all the 
components. Chitosan solution (0.02–0.06 % w/v) was prepared in 1 % v/v acetic acid (pH 
adjusted to 5 using 1 M NaOH). To this was added Pluronic F 127 (0.0–0.025 % w/v) and 
amoxicillin trihydrate (0.01–0.04 % w/v). To the above mixture, 0.1 % w/v aqueous solution 
of ALG (prepared in double distilled water, pH was adjusted to 5.0 using 0.05 M HCl) was 
sprayed with continuous stirring for 30 minutes [36, 43]. The nanoparticles produced were 
collected by centrifugation at 25,000 rpm (42,000 g) for 50 minutes, washed with double 
distilled water and  freeze dried (pre-freezing  at  −20°C in deep freezer) (Martin Christ 
model Alpha 1-2 LD plus) at −55°C, 0.01mm of Hg using D-(+)-Trehalose, dihydrate (0.5 
% w/v) as a cryoprotectant. 
Preparation of Fluorescent CS-ALG PEC nanoparticles 
FITC conjugated Chitosan was prepared by allowing it to react with CS. FITC in methanol 
was prepared as a solution and added into 1 % solution of CS slowly [44]. The reaction 
was allowed to proceed in dark at room temperature for 2 hours. The resultant product 
was precipitated using 0.1 M sodium hydroxide solution, washed extensively with double 
distilled water, until the wash was freed from FITC fluorescence signal. The precipitate 
(FITC labelled chitosan) was freeze dried.  
The FITC labelled CS-ALG nanoparticles were prepared as per the method described 
earlier.  
Optimization, data analysis and model validation of drug loaded CS-ALG PEC 
nanoparticles (Box-Behnken Design) 
The selected method for preparation of nanoparticles involve several formulation variables 
such as pH, concentration of ingredients, stirring speed, mixing volume etc which 
influences the particle size, surface charge on the particles, entrapment efficiency and 
release profile of the nanoparticles. Moreover, there are chances of interactions between 
the various variables which may alter the above mentioned characteristics. Hence, a need 
arose for optimization of the nanoparticle preparation using a suitable design which could 
reduce the number of experimentation protocols. Box–Behnken design fit the requisite 
need of reducing experimentation protocols because 3–factor, 3–level of experimentation 
reduced the total number of experiments to just 15 instead of 27 as per conventional 
optimization techniques [45]. Design Expert software (Version 8.0.1, Stat-Ease) was used 
to explore the response surfaces and to construct second order polynomial models [46].   Amoxicillin Loaded Chitosan–Alginate Polyelectrolyte Complex Nanoparticles as Mucopenetrating … 687 
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High drug entrapment and stability with optimum particle size are essential features for 
nanoparticulate delivery systems. Hence, for the present study, constraints like particle 
size (≥600 nm), zeta potential (≥ +35 mV) and maximum percent drug entrapment (PDE) 
were fixed.  
A design matrix comprising of fifteen experimental runs was constructed, for which the 
non-linear computer generated quadratic model is defined as;  
Eq. 4.  Y = b0 + b1A + b2B + b3C + b12A*B + b13A*C + b23B*C + b11A
2 + b22B
2 + b33C
2 
Where, Y = measured response associated with each factor level combination; b0  = 
intercept; b1 to b33 are regression coefficients computed from the observed experimental 
values of Y from experimental runs; and A, B and C are the coded levels of independent 
variables [47, 48]. Table 1 lists the independent variables studied i.e. concentration of CS 
(A), Amoxicillin (B) and Pluronic F-127 (C) in the formulation, along with their levels, 
selected on the basis of preliminary experimentation [49]. The designed fifteen 
experimental formulations, with respective concentrations of formulation variables and the 
corresponding observations for dependent variables like particle size (Y1), zeta potential 
(Y2) and PDE (Y3) are given in Table 2. The responses obtained were fitted to first order, 
second order and quadratic-models and evaluated for statistical significance and r
2 values. 
Three-dimensional response surface plots were generated by Design Expert 8.0.1 
software. Finally, three optimal checkpoint formulations were selected to validate the 
chosen experimental domain and polynomial equations. The resultant experimental values 
of the responses were statistically compared and validated [46]. 
Stability of Amoxicillin in simulated gastric fluid (pH 1.2) 
10 mg of amoxicillin was dissolved in simulated gastric fluid (pH 1.2) in a 50ml volumetric 
flask and maintained at 37°C [40]. The % degradation of the drug in SGF was determined 
at 0, 1, 2, 3, 4 and 6 hours, spectrophotometrically, at 272.6 nm.  
Characterization of Nanoparticles 
Percentage yield 
The unentrapped drug from drug loaded CS-ALG PEC nanoparticles was removed by 
washing with distilled water (thrice). Washed nanoparticles were re-dispersed in distilled 
water and subjected to lyophilisation. Lyophilized nanoparticles were analyzed for yield 
[48].  
The nanoparticles yield was calculated using the following equation:  
Eq. 5.  100   
s ingredient   all   of   Mass
recoverd   les nanopartic   of   Mass
    les Nanopartic   of    Yield % × =  
Entrapment efficiency (PDE) 
The percent of drug entrapment of drug loaded nanoparticles were calculated as below: 688  S. Arora et al.:   
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Nanoparticles were digested in acetic acid for 20 minutes and centrifuged at 1000 rpm for 
5 minutes. The supernatant was withdrawn, filtered and estimated for drug content [29]. 
The % drug entrapment was calculated using the following equation: 
Eq. 6.  100   
added   drug   of   amount   Total
les nanopartic   in   present   drug   of   Amount
    (PDE)   Entrapment   % × =  
Drug release profile 
Drug loaded CS-ALG PEC nanoparticles were evaluated for release in SGF (pH 1.2). 
Accurately weighed nanoparticles were dispersed in water and kept in a pre-treated 
dialysis tube membrane in SGF (pH 1.2) at 37 ± 1°C with continuous stirring. Aliquots were 
withdrawn at 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0 and 6.0 hours, filtered through 0.22 
μm membrane filter and analysed for drug content [48]. 
Particle size and Zeta potential 
Size distribution and zeta potential of drug loaded CS-ALG PEC nanoparticles were done 
using Zetasizer (Beckman Coulter, Delsa nano C). All measurements were obtained in 
triplicate (n = 3) [18]. 
Surface Morphology  
Drug loaded CS-ALG PEC nanoparticles were subjected to surface electron microscopy 
(SEM,  ZEISS EVO 50) [51]. Freeze dried nanoparticles were mounted on aluminium 
sample holder and gold coated for morphological analysis with an applied voltage of 20 kV 
at various magnifications. 
Polymer–Drug / polymer–polymer interaction studies 
FTIR (Thermo nicolet-380) was performed on freeze dried CS-AlG PEC nanoparticles to 
assess the interaction between amino groups of CS and carboxylic groups of ALG using 
potassium bromide (KBr) discs, compressed at 100kg/cm
2 with an hydraulic pellet press 
and scanned at 4 mm/s at a resolution of 2 cm over a wave number region of   
400–4000 cm
−1.  
Mucoadhesion & Mucopenetration studies 
(a) Bioadhesion Force studies 
Drug loaded CS-ALG PEC nanoparticles were subjected for studies to calculate the force 
required to detach from gastric mucosal tissue as per the modified method of ElHady SSA 
[52] using wistar rats.  
(b) In-vitro mucoadhesion studies 
The percentage mucoadhesion was calculated by count number method using Neubauer’s 
chamber (haemocytometer) [53]. The previously counted number of FITC-labelled CS-
ALG PEC nanoparticles (n1) (10 mg of nanoparticles dispersed in 2 ml of double distilled 
water) were filled in the pre-excised & washed isolated rat stomach, closed from one end. 
After 20 minutes of incubation at 37°C, stomach was washed with 0.9%w/v NaCl solution 
(thrice) and the washings were collected. These washings were analysed for total   Amoxicillin Loaded Chitosan–Alginate Polyelectrolyte Complex Nanoparticles as Mucopenetrating … 689 
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nanoparticles count (n2) under gamma effect of Motic digital microscope in 100 X. Similar 
studies were performed using FITC-labelled  CS-TPP nanoparticles (using tripoly-
phosphate anions (TPP) as cross linking agent) for comparative evaluation of muco-
adhesion. 
(c) in-vivo mucopenetration studies 
The animal studies experimental protocol was approved by the Institutional Animal Ethics 
Committee (IAEC) in accordance with Committee for the Purpose of Control and 
Supervision of Experiments on Animals (India) (CPSCEA) guidelines. Twelve healthy male 
Wistar rats (170–230 g), fasted overnight, subjected to standard laboratory conditions (i.e. 
room temperature, 23 ± 2°C; relative humidity, 50 ± 5%; 12/12 hours light/dark cycle), 
were administered with 10 mg / 2 ml of FITC labelled CS-ALG PEC nanoparticles using 
oral feeding canula. The animals were sacrificed at time intervals of 1, 2, 4 and 6 hours. 
The stomach was excised, washed (0.9%w/v NaCl solution), fixed (antrum region) in 10 % 
formalin, sectioned to a thickness of 5micronm and stained with eosin. [47] The fixed 
stained tissue sections were evaluated under Digital microscope (100X) (Motic DMWB 
series) and inverted fluorescent microscope 40X (Olympus) to analyse the muco-
penetration and localization of fluorescent CS-ALG PEC nanoparticles.  
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